Literature DB >> 8665688

Immunoassay for intact amino-terminal propeptide of human type I procollagen.

J Melkko1, S Kauppila, S Niemi, L Risteli, K Haukipuro, A Jukkola, J Risteli.   

Abstract

We have developed quantitative immunoassays for the intact, trimeric amino-terminal propeptide of human type I procollagen (PINP) and its Col1 domain. Intact PINP was isolated from the pleural fluids of cancer patients by a combination of ion-exchange, gel-filtration, and reversed-phase chromatographies. The amino-terminal Col1 domain of PINP was isolated after bacterial collagenase treatment of the heat-denatured trimeric propeptide. For the intact PINP assay we used a polyclonal antibody with only 1.2% cross-reaction with the monomeric Col1 domain. In human serum, this assay detects only one peak of PINP antigenicity that has the size of known intact PINP. Under similar conditions, an assay for the Coll domain of PINP recognized two circulating antigens. The biological relevance was further verified in wound fluid. Interassay and intraassay CVs were 3.1-9.3% for values within the reference intervals (mean +/- 2SD) for intact PINP in serum, which were 19-84 microg/L for women and 20-76 microg/L for men.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8665688

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  41 in total

Review 1.  Clinical utility of bone markers in the evaluation and follow-up of osteoporotic patients: why are the markers poorly accepted by clinicians?

Authors:  J J Stepan
Journal:  J Endocrinol Invest       Date:  2003-05       Impact factor: 4.256

Review 2.  Bone turnover markers: use in osteoporosis.

Authors:  Kim Naylor; Richard Eastell
Journal:  Nat Rev Rheumatol       Date:  2012-06-05       Impact factor: 20.543

3.  Bone mineral density in Klinefelter syndrome is reduced and primarily determined by muscle strength and resorptive markers, but not directly by testosterone.

Authors:  A Bojesen; N Birkebæk; K Kristensen; L Heickendorff; L Mosekilde; J S Christiansen; C H Gravholt
Journal:  Osteoporos Int       Date:  2010-07-24       Impact factor: 4.507

Review 4.  Bone remodeling markers: assessment of fracture risk and fracture risk reduction.

Authors:  Aubrey Blumsohn
Journal:  Curr Osteoporos Rep       Date:  2003-12       Impact factor: 5.096

5.  Molecular markers of cartilage breakdown and synovitis at baseline as predictors of structural progression of hip osteoarthritis. The ECHODIAH Cohort.

Authors:  B Mazières; P Garnero; A Guéguen; M Abbal; L Berdah; M Lequesne; M Nguyen; J-P Salles; E Vignon; M Dougados
Journal:  Ann Rheum Dis       Date:  2005-12-01       Impact factor: 19.103

6.  Training-induced changes in peritendinous type I collagen turnover determined by microdialysis in humans.

Authors:  H Langberg; L Rosendal; M Kjaer
Journal:  J Physiol       Date:  2001-07-01       Impact factor: 5.182

7.  Effect of impact exercise on bone metabolism.

Authors:  A Vainionpää; R Korpelainen; H K Väänänen; J Haapalahti; T Jämsä; J Leppäluoto
Journal:  Osteoporos Int       Date:  2009-03-05       Impact factor: 4.507

8.  A randomised controlled trial of short term growth and collagen turnover in asthmatics treated with inhaled formoterol and budesonide.

Authors:  C Heuck; L Heickendorff; O D Wolthers
Journal:  Arch Dis Child       Date:  2000-10       Impact factor: 3.791

Review 9.  Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability.

Authors:  P Szulc; K Naylor; N R Hoyle; R Eastell; E T Leary
Journal:  Osteoporos Int       Date:  2017-06-19       Impact factor: 4.507

Review 10.  Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club.

Authors:  P Bergmann; J-J Body; S Boonen; Y Boutsen; J-P Devogelaer; S Goemaere; J-M Kaufman; J-Y Reginster; V Gangji
Journal:  Int J Clin Pract       Date:  2009-01       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.